You have successfully completed the newsletter registration.
We are pleased to welcome you in our mailing list!
Best regards
Your MetrioPharm Blog team
MetrioPharm AG
Bleicherweg 45
CH-8002 Zurich
Newsletter subscription completed
- 13.03.2024 MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
- 31.01.2024 MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
- 25.10.2023 MetrioPharm Receives Rare Pediatric Disease Designation (RPDD) for MP1032 from the U.S. FDA
- 30.05.2023 MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy